ENXTPA:ALSEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Sensorion's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALSEN is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ALSEN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of French stocks.


Market Performance


7 Day Return

0.8%

ALSEN

3.0%

FR Biotechs

1.1%

FR Market


1 Year Return

24.1%

ALSEN

35.5%

FR Biotechs

-2.6%

FR Market

Return vs Industry: ALSEN underperformed the French Biotechs industry which returned 27.7% over the past year.

Return vs Market: ALSEN exceeded the French Market which returned -3% over the past year.


Shareholder returns

ALSENIndustryMarket
7 Day0.8%3.0%1.1%
30 Day15.5%12.0%15.2%
90 Day-27.8%22.3%11.6%
1 Year24.1%24.1%35.5%35.5%-0.6%-2.6%
3 Year-53.1%-53.1%-31.8%-31.9%16.8%7.1%
5 Year-83.8%-83.8%-63.5%-63.7%48.9%28.7%

Long-Term Price Volatility Vs. Market

How volatile is Sensorion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sensorion undervalued compared to its fair value and its price relative to the market?

2.47x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALSEN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALSEN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALSEN is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: ALSEN is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALSEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALSEN is good value based on its PB Ratio (2.5x) compared to the FR Biotechs industry average (3x).


Next Steps

Future Growth

How is Sensorion forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-17.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALSEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALSEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALSEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALSEN's revenue is expected to decline over the next 3 years (-47.4% per year).

High Growth Revenue: ALSEN's revenue is forecast to decline over the next 3 years (-47.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALSEN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sensorion performed over the past 5 years?

-20.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALSEN is currently unprofitable.

Growing Profit Margin: ALSEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALSEN is unprofitable, and losses have increased over the past 5 years at a rate of 20.2% per year.

Accelerating Growth: Unable to compare ALSEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALSEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).


Return on Equity

High ROE: ALSEN has a negative Return on Equity (-39.56%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sensorion's financial position?


Financial Position Analysis

Short Term Liabilities: ALSEN's short term assets (€32.7M) exceed its short term liabilities (€3.7M).

Long Term Liabilities: ALSEN's short term assets (€32.7M) exceed its long term liabilities (€1.9M).


Debt to Equity History and Analysis

Debt Level: ALSEN's debt to equity ratio (0.7%) is considered satisfactory.

Reducing Debt: ALSEN's debt to equity ratio has reduced from 10.1% to 0.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALSEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALSEN has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 19.2% each year.


Next Steps

Dividend

What is Sensorion current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALSEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALSEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALSEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALSEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALSEN's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Nawal Ouzren (42 yo)

3.58yrs

Tenure

Mrs. Nawal Ouzren has been Chief Executive Officer of Sensorion SA since April 2017. Mrs. Ouzren has been Director at Inventiva S.A. since May 7, 2019. Mrs. Ouzren has 15 years of experience in operational...


Leadership Team

NamePositionTenureCompensationOwnership
Nawal Ouzren
CEO & Director3.58yrsno datano data
Géraldine Honnet
Chief Medical Officer0.75yrno datano data
Juergen Heitmann
Chief Business Officer1.17yrsno datano data

1.2yrs

Average Tenure

Experienced Management: ALSEN's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Nawal Ouzren
CEO & Director3.58yrsno datano data
Edwin Moses
Chairman of the Board0.33yrno datano data
Chahra Louafi
Directorno datano datano data
Khalil Barrage
Director1.33yrsno datano data
Cédric Moreau
Independent Director1.33yrsno datano data
Julien Miara
Director1.33yrsno datano data
Eric de La Fortelle
Independent Directorno datano datano data
Frederic Venail
Member of Scientific Advisory Boardno datano datano data
Jean-François Morin
Directorno datano datano data
Steven Rauch
Member of Scientific Advisory Boardno datano datano data
A. Ernst
Member of Scientific Advisory Boardno datano datano data
Christine Petit
Chair of Scientific Advisory Board2.5yrsno datano data

1.3yrs

Average Tenure

52yo

Average Age

Experienced Board: ALSEN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 338.9%.


Top Shareholders

Company Information

Sensorion SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sensorion SA
  • Ticker: ALSEN
  • Exchange: ENXTPA
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €97.434m
  • Shares outstanding: 76.72m
  • Website: https://www.sensorion-pharma.com

Number of Employees


Location

  • Sensorion SA
  • 375, rue du Professeur Joseph Blayac
  • Montpellier
  • Languedoc-Roussillon
  • 34080
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALSENENXTPA (Euronext Paris)YesCommon StockFREURApr 2015
RFMBST (Boerse-Stuttgart)YesCommon StockDEEURApr 2015

Biography

Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. The company develops SENS-111, which is in phase II clinical trials to treat acute unilateral vestibu...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 19:32
End of Day Share Price2020/11/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.